Journal
BULLETIN OF THE KOREAN CHEMICAL SOCIETY
Volume 33, Issue 2, Pages 433-442Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.5012/bkcs.2012.33.2.433
Keywords
Gene therapy; Cancer; Clinical trial; Liposome
Categories
Funding
- Basic Science Research Program
- National Research Foundation of Korea (NRF)
- Ministry of Education, Science and Technology [2011-0007990, 2011-003093]
- Ministry of Health & Welfare, Republic of Korea [A111227]
- American Health Assistance Foundation [A2010646]
- Korea Health Promotion Institute [A111227] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [2011-0007990] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The promise of stem cell therapy for various clinical applications seems getting realistic. An increasing number of researchers, from virtually every discipline of natural sciences, are flocking into this new world. Only ten years ago, gene therapy was the medicine for the 21st century. The possibility was endless. Although the science itself underlying gene therapy was very young, the field was exploding under the optimism that this new medicine would revolutionize both the basic and clinical sciences. For many reasons, the initial target was cancer. Here, we will focus on the results of cancer gene therapy clinical trials using liposome or nonviral gene carrier, hoping that the lesson from here will be a guideline for the new generation of cell-based therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available